sábado, 7 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

Synopsys outlines $9.56B–$9.66B revenue target for 2026 as Ansys integration advances

View original at seekingalpha.com
Synopsys outlines $9.56B–$9.66B revenue target for 2026 as Ansys integration advances Earnings Call Insights: Synopsys (SNPS) Q1 2026 MANAGEMENT VIEW * CEO Sassine Ghazi highlighted a strong start to Synopsys’ 40th anniversary year, emphasizing an expanded portfolio and leadership positions, stating, "In Q1, we achieve…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Reiterating full year revenue, non-GAAP operating margin and cash flow guidance while raising non-GAAP EPS guidance for the full year

    80% confidence
  • Confidence in IP business pickup is driven by the design starts and the breadth of the portfolio

    80% confidence
  • Feeling great about the progress being made on the roadmap

    80% confidence
  • Classic Synopsys was down slightly in China, whereas Ansys portfolio performed fairly well due to export restrictions and customer behavior shifts to domestic foundries

    80% confidence
  • There's a much bigger opportunity and growth opportunity for the interface IP, which is where investments will focus

    80% confidence
  • AI isn't disrupting our business. It's amplifying our strategic advantage.

    80% confidence
  • The first half of 2026 will deliver the first wave of joint Synopsys-Ansys solutions; monetization to start in FY 2027

    80% confidence
  • Q1 '26 marked a strong start to the year with revenue at the upper end of guided range, non-GAAP operating margin of 42.1% and non-GAAP EPS above guidance

    80% confidence
  • Synopsys won a marquee emulation win versus the incumbent at a leading AI HPC customer

    80% confidence
  • Hardware business had a record year last year and expectation is to continue delivering given demand and complexity

    80% confidence
  • AI agents for chip design cannot hallucinate and must be 100% accurate as you move through the workflow

    80% confidence
  • With muted growth in IP, we get muted operating margin; expectation is that once titles are on time, it's a very good business

    80% confidence
  • Q1 2026 achieved revenue at the high end of guidance and non-GAAP EPS exceeded guidance

    80% confidence
  • Synopsys has the right skills and is putting the right resources and priority to deliver on time and schedule for IP titles

    80% confidence
  • 2026 is the year Synopsys begins delivering on the technology promise of the Synopsys plus Ansys combination

    80% confidence
  • Backlog building and consumption is an ebb and flow; sitting at $11.3 billion of backlog feels great

    80% confidence
  • Ansys now supports more than 90% of the top 100 automotive suppliers

    80% confidence
  • Advanced nodes saw 100% usage on critical tape-outs at 2-nanometer and below

    80% confidence
  • 2026 is a transitional year for Design IP segment, with focus on aligning the fastest-growing segments of the silicon market

    80% confidence
  • Backlog ended at $11.3 billion, underscoring strong and resilient business model

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com